Study finds that CysLTR1 blockade slows tumor growth and enhances survival in cancer — Evidence Review
Published in Nature Cancer, by researchers from Northwestern University Feinberg School of Medicine, Lund University
Researched by
— the AI search engine for science
Table of Contents
A new study suggests that the common asthma drug montelukast may help overcome resistance to immunotherapy in hard-to-treat cancers by targeting the CysLTR1 receptor. Most related research supports the idea that blocking CysLTR1 can slow tumor growth and improve treatment response, reinforcing these findings from the original study.
- Multiple studies indicate that CysLTR1 signaling promotes tumor growth, drug resistance, and immune evasion; antagonizing this pathway—often with montelukast—reverses these effects in preclinical cancer models 1 2 3 4 5.
- High CysLTR1 expression in tumors is consistently linked to poor prognosis and resistance to therapy, while its inhibition reduces tumor proliferation, metastasis, and immunosuppression 1 2 3 5.
- Existing literature on repurposed non-cancer drugs (such as antipsychotics and anti-allergic agents) for solid tumors, including breast cancer, shows similar promise for targeting non-traditional pathways in overcoming drug resistance and metastasis 12 5 4.
Study Overview and Key Findings
Resistance to immunotherapy remains a significant challenge in treating aggressive and hard-to-treat cancers such as triple-negative breast cancer. This new research investigates whether the cysteinyl leukotriene receptor 1 (CysLTR1), a protein known for its role in immune and allergic responses, can be therapeutically targeted to improve outcomes in cancer patients. The study is particularly timely, as it leverages an already-approved asthma drug, montelukast, and offers a potential new use for existing medications to address cancer therapy resistance, a major clinical need.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Northwestern University Feinberg School of Medicine, Lund University |
| Journal Name | Nature Cancer |
| Authors | Tang, H., Xie, P., Ahn, J., Zhang, B. |
| Population | Lab mice, human blood samples |
| Methods | Animal Study |
| Outcome | Tumor growth, survival time, immunotherapy response |
| Results | Blocking CysLTR1 slowed tumor growth and increased survival |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database of over 200 million research papers. The following search queries were used to identify relevant literature:
- CysLTR1 blockers cancer treatment efficacy
- asthma drug cancer survival outcomes
- breast cancer tumor growth inhibition
Below, we summarize key themes and findings from the related studies:
| Topic | Key Findings |
|---|---|
| How does CysLTR1 signaling impact tumor growth, metastasis, and therapy resistance? | - CysLTR1 promotes tumor angiogenesis, increases vascular permeability, and supports tumor growth and metastasis; antagonists reduce tumor growth and metastasis in animal models 1 4 5. - High CysLTR1 expression is linked to drug resistance, stemness, and poor prognosis; blocking CysLTR1 reverses these features in preclinical models 2 3 4. |
| Can montelukast or other CysLTR1 antagonists be repurposed as anti-cancer agents? | - Montelukast suppresses proliferation and progression in several cancer types, including colon and pancreatic cancer, and may act as a chemopreventive agent 2 5 4. - Montelukast, in combination with other therapies, can overcome acquired resistance and reduce stemness in cancer cells 2 3. |
| Are there links between asthma, asthma medications, and cancer incidence or outcomes? | - Asthma is associated with increased risk of certain cancers, but inhaled corticosteroids may lower lung cancer risk in asthma patients 6 8. - Some anti-asthma and allergy drugs, including montelukast, may have protective or therapeutic effects in cancer, possibly due to their impact on inflammatory signaling pathways 5 4. |
| What is the evidence for repurposing non-cancer drugs to inhibit tumor growth and metastasis in breast cancer? | - Repurposed drugs (e.g., antipsychotics, aspirin, calycosin) can suppress breast tumor growth and metastasis via diverse mechanisms, offering additional therapeutic options for drug-resistant and aggressive breast cancer subtypes 12 10 13. - Targeting non-traditional pathways (e.g., integrin, mTORC1, or GPR30 signaling) shows promise in preclinical models 12 10 13. |
How does CysLTR1 signaling impact tumor growth, metastasis, and therapy resistance?
The new study aligns with prior research indicating that CysLTR1 is a crucial mediator of tumor growth, angiogenesis, metastasis, and drug resistance. Preclinical studies consistently demonstrate that genetic or pharmacological inhibition of CysLTR1 reduces tumor burden, suppresses metastasis, and improves therapy outcomes in various cancer models. These findings reinforce the potential for targeting CysLTR1 in the context of immunotherapy resistance.
- CysLTR1 enhances tumor-promoting inflammation and supports the tumor microenvironment, facilitating immune evasion and resistance to therapies 1 4.
- Antagonists of CysLTR1, such as montelukast, decrease tumor vascular leakage and suppress metastasis in animal models 1 5.
- High CysLTR1 expression correlates with increased tumor aggressiveness, stemness, and resistance to chemotherapy and immunotherapy 2 3 4.
- Inhibiting CysLTR1 can reprogram tumor-associated immune cells and sensitize tumors to checkpoint blockade therapies 3 4.
Can montelukast or other CysLTR1 antagonists be repurposed as anti-cancer agents?
Repurposing montelukast, a widely used asthma drug, for cancer therapy is supported by a growing body of preclinical evidence. Studies suggest that montelukast and similar antagonists can inhibit tumor cell proliferation, reduce stemness, and enhance responses to standard treatments, including chemotherapy and immunotherapy.
- Montelukast suppresses proliferation of colon and pancreatic cancer cells, reduces tumor incidence, and induces cell cycle arrest in preclinical models 2 5.
- Combination of montelukast with chemotherapy or immunotherapy produces synergistic anti-tumor effects and overcomes resistance mechanisms 2 3.
- The safety profile and established clinical use of montelukast make it an attractive candidate for drug repurposing, though careful monitoring of side effects is needed 5 4.
Are there links between asthma, asthma medications, and cancer incidence or outcomes?
The relationship between asthma, its treatment, and cancer risk is complex. While asthma has been associated with an increased incidence of some cancers, certain asthma medications (notably inhaled corticosteroids) may lower this risk, particularly for lung cancer. The potential anti-cancer benefits of drugs like montelukast may be related to their effects on inflammatory and immune signaling pathways implicated in both asthma and cancer.
- Asthma is linked to higher risks of cancer development, especially in the early years following diagnosis; the underlying mechanisms may involve chronic inflammation 6 8.
- Inhaled corticosteroids in asthma patients are associated with a reduced risk of lung cancer, suggesting that modulation of airway inflammation might have protective effects 8.
- Montelukast and other anti-allergic drugs show chemopreventive and anti-proliferative effects in animal cancer models 5 4.
What is the evidence for repurposing non-cancer drugs to inhibit tumor growth and metastasis in breast cancer?
Beyond CysLTR1 antagonists, several non-oncology drugs—including certain antipsychotics, anti-inflammatory agents, and plant-derived compounds—have shown efficacy in preclinical breast cancer models. These agents act through diverse molecular pathways and may offer new treatment strategies for resistant or aggressive breast cancer subtypes.
- Penfluridol, an antipsychotic, and aspirin have demonstrated anti-metastatic and growth-suppressive effects in triple-negative and PI3K-mutant breast cancer models, respectively 12 10.
- Calycosin, a phytoestrogen, inhibits both estrogen receptor-positive and -negative breast cancer cell growth through GPR30 signaling 13.
- Targeting alternative pathways (integrin, mTORC1, glycolysis) with repurposed agents may complement standard cancer therapies and help overcome resistance 12 10 11.
Future Research Questions
Although preclinical evidence for CysLTR1 antagonism in cancer is promising, further research is essential to determine clinical efficacy, optimal patient selection, and safety in combination with existing therapies. The following research questions highlight key areas for future investigation:
| Research Question | Relevance |
|---|---|
| What is the clinical efficacy of montelukast in combination with immunotherapy for solid tumors? | Clinical trials are needed to validate whether combining montelukast with checkpoint inhibitors or other immunotherapies improves outcomes in patients with resistant or aggressive cancers, as suggested by preclinical models 3 4 5. |
| Can CysLTR1 expression serve as a predictive biomarker for immunotherapy response in cancer? | Identifying patients most likely to benefit from CysLTR1-targeted therapies could personalize treatment and improve prognostic accuracy; previous studies link high CysLTR1 expression with poor response to existing therapies 2 3 4. |
| What are the mechanisms by which CysLTR1 modulates immune cell function in the tumor microenvironment? | Understanding how CysLTR1 signaling shapes immune suppression and tumor-promoting neutrophil behavior could reveal new targets and refine combination therapy strategies 1 3 4. |
| What are the long-term safety profiles of montelukast and other CysLTR1 antagonists in cancer patients? | Given the neuropsychiatric side effects reported for montelukast in non-cancer settings, thorough safety evaluations are required before widespread clinical adoption in oncology patients 5. |
| Are other approved CysLTR1 antagonists or novel antibodies effective and safer for targeting this pathway in cancer? | Exploring alternative CysLTR1-targeted agents, including monoclonal antibodies, may provide similar therapeutic benefits with fewer adverse effects, as proposed by current research 5 4. |
This evidence-based summary integrates the latest findings on CysLTR1 antagonists in cancer therapy, highlights consensus and emerging trends in the literature, and identifies key directions for future research.